GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of...

GSk宣佈了FIRSt-ENGOt-OV44三期試驗的主要結果，試驗中使用了Zejula（尼拉帕利）和Jemperli（多斯利尤單抗）用於一線晚期卵巢癌，其主要終點無進展生存期達成，關鍵次要終點...

Benzinga · 12/20 17:01

GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of Overall Survival Did Not Meet Statistical Significance

GSk宣佈了FIRSt-ENGOt-OV44 III期試驗的主要結果，該試驗涉及在一線治療晚期卵巢癌中使用Zejula（尼拉帕利）和Jemperli（多沙利單抗），該試驗達到了主要終點——無進展生存期，而關鍵的次要終點——總生存期並未達到統計學顯著性。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。